ArticleNeurochemical research2026
Ginsenoside Rh2 Protects Against Glutamate-Induced Neurotoxicity in PC12 Cells via Activation of the VEGF-mediated PI3K/Akt/mTOR Signaling Pathway.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ginsenoside Rh2 (GRh2), a major active component of red ginseng, exhibits significant neuroprotective effects against glutamate-induced excitotoxicity in differentiated PC12 cells. This study found that GRh2 concentration-dependently reversed the loss of cell viability caused by glutamate. It effectively attenuated key pathological events, including intracellular calcium overload, reactive oxygen species accumulation, and mitochondrial membrane potential collapse. Furthermore, GRh2 enhanced synaptic plasticity, as evidenced by improved neurite morphology and increased levels of the synaptic markers neurogranin and neuromodulin. Mechanistic investigations revealed that GRh2 upregulated vascular endothelial growth factor (VEGF) expression and subsequently activated the PI3K/Akt/mTOR signaling pathway. This activation led to increased expression of synaptic proteins (PSD-95 and synaptophysin), an elevated Bcl-2/Bax ratio. Critically, the specific VEGF inhibitor SU11248 and PI3K inhibitor LY294002 abolished all the protective effects of GRh2, confirming the indispensable role of the VEGF/PI3K/Akt/mTOR axis. These results indicate that GRh2 alleviates glutamate-induced neurotoxicity by activating the VEGF-mediated PI3K/Akt/mTOR pathway, thereby improving mitochondrial function, inhibiting oxidative stress and apoptosis, and promoting synaptic integrity. This work provides novel molecular insights into the neuroprotective mechanism and potential of GRh2.
Indexed as
Identifiers
42095927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.